You are here: Industry Insights > Migraine

News List

Evidence Supports Use of High-Dose Aspirin for Migraine drugs
December 26, 2019
Evidence supports the use of high-dose aspirin for treating acute migraine and low-dose aspirin for prevention of recurrent attacks ...
Ubrogepant Relieves Pain, Symptoms of Acute Migraine drugs
December 25, 2019
The percentage of patients with migraine reporting freedom from pain is higher for those receiving ubrogepant than those receiving placebo, according to a study published in the issue of the New England Journal of Medicine.
Sleep Fragmentation Linked to Odds of Migraine drugs
December 24, 2019
Sleep fragmentation, defined by low sleep efficiency, is associated with increased odds of migraine a day later, but there is no temporal association for short sleep duration and ...
FDA Approves New Treatment for Adults with Migraine americanpharmaceuticalreview
December 24, 2019
The U.S. Food and Drug Administration (FDA) approved Ubrelvy (ubrogepant) tablets for the acute (immediate) treatment of migraine with or without aura ...
Biohaven Achieves Positive Topline Results in Migraine Study americanpharmaceuticalreview
December 18, 2019
Biohaven Pharmaceutical announced positive topline results from its randomized, dose ranging, placebo controlled, pivotal Phase 2/3 clinical trial evaluating the efficacy and tolerability ...
Erenumab migraine drug fails to meet NICE recommendation standards europeanpharmaceuticalreview
September 27, 2019
NICE has announced that it will not be recommending erenumab, an injectable migraine treatment, due to issues with cost and its long-term effectiveness.
New Hope Against a 'Dizzying' Form of Migraine drugs
September 26, 2019
People who suffer bouts of vertigo and dizziness may be suffering from a type of migraine for which treatments rarely work.
Migraines Linked to Higher Risk for Dementia, Alzheimer Disease drugs
September 19, 2019
Migraines are a significant risk factor for Alzheimer disease (AD) and all-cause dementia.Rebecca E. Morton, from University of Waterloo in Canada, and colleagues used data from ...
Impel NeuroPharma Announces Last Patient Enrolled in INP104 Trial for Migraine americanpharmaceuticalreview
September 05, 2019
Impel NeuroPharma announced the last patient has been enrolled in "STOP-301" (Safety and Tolerability of POD-DHE), the Company's pivotal open-label Phase 3, multi-use...
Two lots of migraine medication have been recalled europeanpharmaceuticalreview
August 20, 2019
Pfizer has volountarily recalled the migraine medication Relpax because of the potential presence of Genus Pseudomonas and Burkholderia.

Previous page 1 2 3 4 5 6 7 8 9 Next page